PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients (Q38393692)

2 September 2017

title

PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients (English)

1 reference

2 September 2017

1 reference

8

Bent Ejlertsen

1 reference

2 September 2017

author name string

Charlotte L T Jørgensen

1

1 reference

2 September 2017

Torsten O Nielsen

2

1 reference

2 September 2017

Karsten D Bjerre

3

1 reference

2 September 2017

Shuzhen Liu

4

1 reference

2 September 2017

Brett Wallden

5

1 reference

2 September 2017

Eva Balslev

6

1 reference

2 September 2017

Dorte L Nielsen

7

1 reference

2 September 2017

language of work or name

1 reference

20 December 2013

1 reference

2 September 2017

1 reference

2 September 2017

volume

53

1 reference

2 September 2017

issue

6

1 reference

2 September 2017

page(s)

776-787

1 reference

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III b

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Molecular predictors of response to therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Metastatic behavior of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Direct multiplexed measurement of gene expression with color-coded probe pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

REporting recommendations for tumour MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Use of archived specimens in evaluation of prognostic and predictive biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Through a glass darkly: advances in understanding breast cancer biology, 2000-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

Statistical Significance of Clustering for High-Dimension, Low–Sample Size Data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2013.865076

10.3109/0284186X.2013.865076

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference